Neuroendocrine tumors (NETs) consists of complex group of tumors that develop predominantly in the digestive or respiratory tracts, but can occur in many areas of the body. These tumors arise from ...
Gene therapy company 4D Molecular Therapeutics raises USD 90 Million to collaborate with AstraZeneca and Roche for moving gene therapies into clinical testing 4D Molecular Therapeutics has upraised USD 90 million in venture capital funds for progressing its vector platform and treatments, which use adeno-associate...
Find MoreThe Orphan Drug Act of 1983 was created to encourage pharmaceutical companies to develop drugs for so-called rare or ultra-rare diseases. The National Institutes of Health (NIH) defines rare diseases as afflicting as fewer than 200,000 individuals. Generally speaking, it has worked. Many companies are willing to inv...
Find MoreAbbVie Receives USFDA Approval for Imbruvica Plus Rituximab as First Chemotherapy-Free Combination Treatment for Waldenström's Macroglobulinemia Adults AbbVie announced that the USFDA approved Imbruvica (ibrutinib) plus rituximab (Rituxan) for the treatment of adult patients with Waldenström's macroglobulinemia (W...
Find MoreAlnylam’s Onpattro Receives First-Ever US FDA Approval for Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults US FDA approved Alnylam’s Onpattro (patisiran) lipid complex injection, a first-of-its-kind RNA interference (RNAi) therapeutic, for the treatment of the polyneurop...
Find MoreAstellas’ Ophthalmology Innovation to Strengthen Further With Quethera Acquisition Astellas has acquired Quethera, a gene therapy company headquartered in the UK, which is focused on developing novel treatments for ocular disorders, such as glaucoma. Through this transaction, Astellas has acquired Quethera’s ...
Find MoreSarepta builds in gene therapy with $30M Lacerta deal Sarepta has dampen its enthusiasm for an ongoing gene therapy candidate. Sarepta has made a tie-up with lacerta that will add 3 more programs to 8 already existing and are ready to expand its focus beyond muscular dystrophy. Sarepta has committed to pay Lacerta ...
Find MoreProgenics got FDA Approval on Iobenguane I 131 for Rare Adrenal Gland Tumors A good news for unresectable rare adrenal tumor patients as oncologists now have a new treatment to offer . On July 30, 2018, the Food and Drug Administration approved Progenics Pharmaceuticals iobenguane I for adult and pediatric patient...
Find MoreMucopolysaccharidosis I (MPS I) (Hurler Syndrome) – a lesser developed window Mucopolysaccharidosis (MPS) is a group of rare, hereditary and incurable “storage diseases”, which is named after mucopolysaccharides (sugars bound to proteins). The stored mucopolysaccharides are called as glycosaminoglycans (GAGs). ...
Find MoreNiemann-Pick disease type C (NPC) is a lipid storage disease that can present in infants, children, or adults. Neonates can present with ascites and severe liver disease from infiltration of the liver and/or respiratory failure from infiltration of the lungs. The classic presentation occurs in mid-to-late childhood ...
Find MoreHerpes zoster oticus (HZ oticus) is a viral infection of the inner, middle, and external ear. A resu.....
Find MoreSepsis is a life-threatening organ dysfunction caused by dysregulated host response to infection. Se.....
Find MoreVirtual clinical trials (VCTs) are site-less clinical trials, which utilizes technology along with t.....
Find MoreParoxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction o.....
Find MoreProgressive Supranuclear Palsy (PSP) is a rare progressive disorder resulting from damage that occur.....
Find MoreOsteosarcoma is a kind of bone cancer that originates from the cells that form bones. It is often fo.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.